New Therapy UpdateA Review of Remdesivir for COVID-19: Data to DateMehta, Monica PharmD, MPH; Shyh, Grace I. PharmDAuthor Information From the Department of Pharmacy, New York-Presbyterian Hospital, New York, NY. Disclosures: The authors have no conflicts of interest to report. Correspondence: Grace I. Shyh, PharmD, Department of Pharmacy, New York-Presbyterian Hospital, 170 William Street, New York, NY. E-mail: [email protected]. Cardiology in Review: November/December 2020 - Volume 28 - Issue 6 - p 332-334 doi: 10.1097/CRD.0000000000000337 Buy Metrics Abstract Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir’s historical background, pharmacology, key trials, adverse events, and issues regarding accessibility. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.